Navigation Links
Exemestane plus everolimus increased progression-free survival
Date:12/7/2011

SAN ANTONIO Everolimus in combination with exemestane has shown promise for the treatment of breast cancer.

"For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control," said Gabriel N. Hortobagyi, M.D., FACP, professor of medicine, chair of the department of breast medical oncology and director of the Multidisciplinary Breast Cancer Research Program at the University of Texas MD Anderson Cancer Center in Houston.

Hortobagyi presented findings from Breast Cancer Trials of Oral Everolimus (BOLERO-2), a phase 3 clinical trial, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

BOLERO-2 researchers enrolled 724 postmenopausal patients with HR-positive metastatic breast cancer and evidence of progressive disease while receiving anastrozole or letrozole. They randomly assigned patients to treatment with exemestane plus everolimus or with exemestane plus placebo.

Results revealed a median progression-free interval of 3.2 months for 239 patients treated with exemestane plus placebo. Among the 485 patients treated with exemestane plus everolimus, researchers found a median progression-free interval of 7.4 months, "a highly significant difference," Hortobagyi said.

Clinical benefit rates, which include complete response, partial response, or stable disease exceeding six months, were 25.5 percent among patients treated with exemestane and placebo and 50.5 percent among those treated with exemestane and everolimus.

"The original hypothesis predicted this increased benefit from the combination, based on compelling preclinical experiments and preliminary results from earlier, smaller clinical trials. These results establish a new standard of care for this group of patients," Hortobagyi said.

He continued, "These results highlight the progress being made in understanding the evolving mechanisms of resistance to standard therapies."

Researchers were not yet able to measure survival analysis in BOLERO-2. However, treatment was well tolerated, with oral mucositis, fatigue, pneumonitis and hyperglycemia being the most common side effects.


'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
210-582-7021
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
2. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
3. Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
4. Everolimus improves progression-free survival for patients with rare pancreatic cancer
5. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
6. An important reduction in risk of stent thrombosis with everolimus-eluting stent
7. Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
8. Migraine Linked to Increased Heart Attack Risk
9. Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research
10. Increased HAART coverage associated with 50 percent drop
11. RetireSafe Survey Says Seniors Are Struggling With Increased Costs Without an Increased Social Security Cost of Living Adjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Honolulu, HI (PRWEB) , ... March 30, 2017 , ... ... removal procedures are performed each year, putting it among the top 5 most popular ... a fair number those million-plus procedures will be performed over the next 8-10 weeks. ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... eve of Autism Awareness Month, representatives from Organic Consumers Association, National Health Freedom ... For Health Foundation, A Voice for Choice, Moms Across America, Freedom and Ethics ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) ... a live webinar designed to help nutrition educators and students inform consumers about ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... a letter to President Trump expressing their support for an independent Vaccine Safety ... Ph.D. scientists and one medical journalist, will hold a press conference at ...
(Date:3/29/2017)... ... , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag ... network of more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, ... mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
(Date:3/29/2017)... Research and Markets has announced the addition of ... report to their offering. ... The global orthopedic navigation system market ... geriatric population prone to orthopedic diseases is a key contributing ... forecast period. Osteoarthritis and osteoporosis are most common disorders in ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology: